AstraZeneca PLC or United Therapeutics Corporation: Who Invests More in Innovation?

AstraZeneca's R&D spending dwarfs United Therapeutics by 18 times.

__timestampAstraZeneca PLCUnited Therapeutics Corporation
Wednesday, January 1, 20145579000000242549000
Thursday, January 1, 20155997000000245098000
Friday, January 1, 20165890000000147600000
Sunday, January 1, 20175757000000264600000
Monday, January 1, 20185932000000357900000
Tuesday, January 1, 201959580000001182600000
Wednesday, January 1, 20205991000000357700000
Friday, January 1, 20219736000000540100000
Saturday, January 1, 20229762000000322900000
Sunday, January 1, 202310935000000408000000
Monday, January 1, 202413583000000
Loading chart...

Unleashing insights

Innovation Investment: AstraZeneca vs. United Therapeutics

In the competitive world of pharmaceuticals, innovation is key. AstraZeneca PLC and United Therapeutics Corporation are two giants in the industry, each with a unique approach to research and development (R&D). From 2014 to 2023, AstraZeneca consistently outpaced United Therapeutics in R&D spending, investing nearly 18 times more on average. In 2023, AstraZeneca's R&D expenses reached a peak, marking a 96% increase from 2014. Meanwhile, United Therapeutics saw a significant spike in 2019, with a 388% increase from the previous year, but overall, their investment remained modest compared to AstraZeneca. This trend highlights AstraZeneca's commitment to innovation, potentially driving future breakthroughs. As the pharmaceutical landscape evolves, these investments could shape the future of healthcare, offering new treatments and therapies to patients worldwide.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025